Compare HI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HI | JANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | HI | JANX |
|---|---|---|
| Price | $31.89 | $15.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $32.00 | ★ $62.00 |
| AVG Volume (30 Days) | 812.0K | ★ 2.5M |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,673,800,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $52.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.36 | $15.16 |
| 52 Week High | $35.59 | $64.90 |
| Indicator | HI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 68.23 | 28.72 |
| Support Level | $31.80 | $16.00 |
| Resistance Level | $32.07 | $17.13 |
| Average True Range (ATR) | 0.10 | 1.55 |
| MACD | -0.09 | -1.31 |
| Stochastic Oscillator | 58.89 | 0.99 |
Hillenbrand Inc is a industrial company that provides engineered processing equipment and solutions to customers around the world. The company operates through two segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment and also provider of engineered process and material handling equipment, systems, and aftermarket parts and services for a variety of industries, including durable plastics, food, and recycling. Molding Technology Solutions has a comprehensive product portfolio that includes injection molding and extrusion equipment, It earns it revenue from Advanced Process Solutions, and Geographically from America, following by Asia and EMEA.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.